Apararenone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Apararenone
Apararenone.svg
Clinical data
Synonyms MT-3995
Routes of
administration
Oral
Drug class Antimineralocorticoid
Identifiers
CAS Number
  • 945966-46-1
PubChem CID
  • 24744336
ChemSpider
  • 28663572
UNII
  • 832663U2NB
ChEMBL
  • CHEMBL2181929
Chemical and physical data
Formula C17H17FN2O4S
Molar mass 364.391 g/mol
3D model (JSmol)
  • Interactive image

Apararenone (INN) (developmental code name MT-3995) is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi Tanabe Pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.[1][2][3] It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication.[1] Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (Ki < 50 nM), the receptor for aldosterone.[1][2][3] As of 2017, it is in phase II clinical trials.[1]

See also

References

  1. ^ a b c d http://adisinsight.springer.com/drugs/800032686
  2. ^ a b Yang J, Young MJ (2016). "Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences". Curr Opin Pharmacol. 27: 78–85. doi:10.1016/j.coph.2016.02.005. PMID 26939027.
  3. ^ a b Kolkhof P, Nowack C, Eitner F (2015). "Nonsteroidal antagonists of the mineralocorticoid receptor". Curr. Opin. Nephrol. Hypertens. 24 (5): 417–24. doi:10.1097/MNH.0000000000000147. PMID 26083526.

External links

  • Apararenone - AdisInsight



Retrieved from "https://en.wikipedia.org/w/index.php?title=Apararenone&oldid=799154003"
This content was retrieved from Wikipedia : http://en.wikipedia.org/wiki/Apararenone
This page is based on the copyrighted Wikipedia article "Apararenone"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA